Neogenomics Inc (NASDAQ: NEO) stock suffered a major decline of -20.6% on 1/10/25. The shares closed at $14.77. Moreover, this decline was accompanied by exceptionally high trading volume at 342% of normal. Relative to the market the stock has been strong over the last nine months but has declined -10.4% during the last week.
Current PriceTarget Research Rating
Neogenomics has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Neogenomics has a poor Appreciation Score of 27 but a good Power Rating of 81, producing the Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment